Becton Dickinson (BD) and BioGX have submitted emergency use authorization (EUA) applications to the U.S. Food and Drug Administration (FDA) for their novel coronavirus test kits.
If authorized, the kits would increase U.S. capacity for screening by thousands of tests per day, the two firms said. Both tests will run on the BD Max molecular diagnostic platform, which is already in use in almost every U.S. state, according to the companies.
